NCT04662931 - An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG

crizanlizumab

Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.

Trial Locations (7)

226014

Novartis Investigative Site, Lucknow

492099

Novartis Investigative Site, Raipur

500082

Novartis Investigative Site, Hyderabad

673008

Novartis Investigative Site, Kozhikode

700014

Novartis Investigative Site, Kolkata

751003

Novartis Investigative Site, Bhubaneswar

781003

Novartis Investigative Site, Guwahati